Protagonist Therapeutics co-discovered ICOTYDE with Johnson & Johnson and subsequently licensed the technology to Janssen Biotech.
Steady: 0 in the last 7 days
Updated sep 23
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Protagonist Therapeutics co-discovered ICOTYDE with Johnson & Johnson and subsequently licensed the technology to Janssen Biotech.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- J&J and Janssen Biotech jointly won summary judgment in a Virginia court regarding J&J's acquisition, with FTC filing an amicus brief.Sub-event
Protagonist Therapeutics licenses ICOTYDE technology to Janssen Biotech after co-discovery with J&J.1 source
Protagonist filed NDA for icotrokinra with FDA, following licensing to Janssen Biotech.1 source
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Janssen Biotech
Biotechnology company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- pr-inside.com
- stockhouse.com
- ACCESS NewswireProtagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist